A clear clinical focus
Primary headache disorders, beginning with acute migraine. A defined problem guides the development program.
SCIENCE WITH A CLEAR PURPOSE
A new direction
for acute migraine.
Advancing natural compounds into precisely formulated pharmaceutical candidates. Built on science. Focused on the people who need better options.
LEAD PROGRAM BioTheraMin™ · Pre-clinical development
PRECISION FORMULATION
1:2 THC:CBD
DESIGNED FOR
Subcutaneous delivery
1:2 THC:CBD
Subcutaneous delivery
Product concept. Not a validated or approved device.
01 / THE OPPORTUNITY
An unmet need.
A focused development strategy.
When a migraine hits,
time matters.
Existing treatments help many people. They don’t help everyone.
Non-response, tolerability, contraindications and nausea can leave some patients without a suitable acute option. BlueThera is developing a different approach: a defined cannabinoid formulation, delivered through a subcutaneous injectable concept.
Explore our lead program ↗Pharmaceutical precision
Standardized formulations and a planned drug-device pathway, supported by formulation, regulatory and manufacturing work.
An operating foundation
A Health Canada–licensed facility in Brooks, Alberta, and experience spanning extraction science and regulated manufacturing.
02 / OUR LEAD PROGRAM
PRE-CLINICALMeet BioTheraMin.™
A cannabinoid-based subcutaneous injectable
for acute migraine.
NATURAL COMPOUNDS.
DEFINED FORMULATION.
DEFINED FORMULATION.
CONCEPTUAL PRODUCT MOCK-UPA defined combination
The proposed active combination is 1:2 THC:CBD. Published cannabinoid research informs the rationale for further pharmaceutical development.
A considered route
Subcutaneous administration has an established role in acute migraine treatment.
Designed around the moment
A preconfigured auto-injector concept intended to support at-home administration.
THE BIOTHERAMIN INTRODUCTION
A closer look at
what we’re developing.
BioTheraMin is an investigational product in development. It has not been approved for sale or established as safe or effective for acute migraine.
03 / THE INVESTMENT THESIS
A focused program.A platform built for execution.
An opportunity built on
more than a molecule.
Research-informed
development
Published research provides a clinical signal for cannabinoid combinations in migraine. Our opportunity is to develop an injectable pharmaceutical candidate.
Capabilities that
connect
Controlled-substance licensing, and an auto-injector platform form a foundation.
Experience across
the critical disciplines
Drug development, regulatory expertise, manufacturing and capital planning come together in a team built for cross-functional execution.
04 / THE DEVELOPMENT PLATFORM
From formulationto clinical evidence.
Good science needs
the right foundation.
BlueThera’s approach brings natural-compound science and pharmaceutical execution into the same development strategy.
BROOKS, ALBERTA · CANADA
6,500square feetA manufacturing
foundation for the future.
Our 6,500 sq. ft. facility brings controlled-substance, cannabis-processing and natural-health-product licensing into a single operating foundation.
Sterile injectable fill-finish and ISO 13485 implementation are planned development activities.
01Extraction science −
Proprietary extraction science and technology support BlueThera’s natural-compound development approach. A patent application for a natural psilocybin extraction process supports our focus on process development.
02Regulated operations +
An existing Health Canada–licensed facility provides an operational base.
03Drug-device development +
BioTheraMin pairs a proposed pharmaceutical formulation with an established auto-injector platform.
04Milestone-led execution +
Pre-clinical studies, manufacturing development and regulatory engagement are intended to build the evidence needed for a future clinical program.
05 / RESEARCH PROGRAMS
Focused today.
Broader scientific potential.
Our lead program is acute migraine. BlueThera’s broader research interests explore natural compounds across primary headache disorders.
PROGRAMRESEARCH FOCUSAPPROACHPOSITIONING
BioTheraMin™
Acute migraineCannabinoid-based injectable conceptLead program · Pre-clinicalBioTheraCinCH™
Preventative cluster headache therapyPsilocybin-based researchExploratory research interestBioTheraCinMH™
Preventative migraine therapyPsilocybin-based researchExploratory research interestResearch programs are investigational. Descriptions are not claims of clinical efficacy or regulatory approval.
06 / OUR PEOPLE
Scientific depth.Operating experience.
The disciplines to
move a program forward.
CORPORATE DEVELOPMENT & FINANCE
Alon Wolfman
President/ Co-Founder
20+ years in business and corporate development. US CPA.
DRUG DEVELOPMENT & REGULATORY
John Simon
CEO/Co-Founder
30+ years in pharma, with experience across FDA and Health Canada submissions and clinical trials.
EXTRACTION SCIENCE & R&D
Christianne Street, PhD
Chief Technology Officer
PhD in supercritical CO₂ extraction technology.
OPERATIONS & PROJECT DELIVERY
Luz Elana Parra
Vice President, Operations
Operations, project management and facility construction.
BIOTECH & CORPORATE STRATEGY
Brad Thompson
Corporate Advisor
39 years in biotech. Former CEO of two NASDAQ-listed companies and co-founder of 18 biotechs.
LET’S TALK ABOUT WHAT COMES NEXT.
Be part of
the next chapter.
For investment discussions, strategic partnerships or a closer look at the development program, connect with us.
info@bluethera.com ↗